Loading clinical trials...
Loading clinical trials...
The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Admini...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Avidity Biosciences, Inc.
Collaborators
NCT06672237 · Neuromuscular Disease, Neuromuscular Diseases (NMD), and more
NCT07360626 · Musculoskeletal Disorders (MSDs), Musculoskeletal Diseases or Conditions
NCT06243848 · Musculoskeletal Diseases, Median Nerve Disease, and more
NCT05742776 · Musculoskeletal Diseases, Median Nerve Disease, and more
NCT06773169 · Neurological Conditions, Musculoskeletal Diseases or Conditions, and more
Arkansas Children's Hospital
Little Rock, Arkansas
Rare Disease Research
Atlanta, Georgia
Gillette Children's
Saint Paul, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions